{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:30:05Z","timestamp":1790713805163,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gaucher disease (GD) is an autosomal recessive disorder caused by mutations in the acid \u03b2-glucocerebrosidase (GCase; GBA) gene. The hallmark of GD is the presence of lipid-laden Gaucher macrophages, which infiltrate bone marrow and other organs. These pathological macrophages are believed to be the sources of elevated levels of inflammatory mediators present in the serum of GD patients. The alteration in the immune environment caused by GD is believed to play a role in the increased risk of developing multiple myeloma and other malignancies in GD patients. To determine directly whether Gaucher macrophages are abnormally activated and whether their functional defects can be reversed by pharmacological intervention, we generated GD macrophages by directed differentiation of human induced pluripotent stem cells (hiPSC) derived from patients with types 1, 2, and 3 GD. GD hiPSC-derived macrophages expressed higher levels of tumor necrosis factor \u03b1, IL-6, and IL-1\u03b2 than control cells, and this phenotype was exacerbated by treatment with lipopolysaccharide. In addition, GD hiPSC macrophages exhibited a striking delay in clearance of phagocytosed red blood cells, recapitulating the presence of red blood cell remnants in Gaucher macrophages from bone marrow aspirates. Incubation of GD hiPSC macrophages with recombinant GCase, or with the chaperones isofagomine and ambroxol, corrected the abnormal phenotypes of GD macrophages to an extent that reflected their known clinical efficacies. We conclude that Gaucher macrophages are the likely source of the elevated levels of inflammatory mediators in the serum of GD patients and that GD hiPSC are valuable new tools for studying disease mechanisms and drug discovery. Stem Cells \u00a02014;32:2338\u20132349<\/jats:p>","DOI":"10.1002\/stem.1732","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T13:12:58Z","timestamp":1399381978000},"page":"2338-2349","source":"Crossref","is-referenced-by-count":92,"title":["Gaucher iPSC-Derived Macrophages Produce Elevated Levels of Inflammatory Mediators and Serve as a New Platform for Therapeutic Development"],"prefix":"10.1093","volume":"32","author":[{"given":"Leelamma M.","family":"Panicker","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lun","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea Soon","family":"Park","sequence":"additional","affiliation":[{"name":"Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Division of Pediatric Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias T.","family":"Zambidis","sequence":"additional","affiliation":[{"name":"Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Division of Pediatric Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judi A.","family":"Sgambato","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"2022011201141290100_stem1732-bib-0001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/978-1-4419-6741-1_11","article-title":"Glucosylceramide in Humans","volume":"688","author":"Messner","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"2022011201141290100_stem1732-bib-0002","first-page":"3635","author":"Beutler","year":"2001"},{"key":"2022011201141290100_stem1732-bib-0003","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","article-title":"Gaucher disease: Pathological mechanisms and modern management","volume":"129","author":"Jmoudiak","year":"2005","journal-title":"Br J Haematol"},{"key":"2022011201141290100_stem1732-bib-0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: Complexity in a \"simple\" disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol Genet Metab"},{"key":"2022011201141290100_stem1732-bib-0005","first-page":"205","article-title":"Cytokines in Gaucher\u2019s disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"2022011201141290100_stem1732-bib-0006","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J Clin Invest"},{"key":"2022011201141290100_stem1732-bib-0007","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene. Nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J Biol Chem"},{"key":"2022011201141290100_stem1732-bib-0008","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme replacement for lysosomal diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annu Rev Med"},{"key":"2022011201141290100_stem1732-bib-0009","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2022011201141290100_stem1732-bib-0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2022011201141290100_stem1732-bib-0011","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1111\/j.1742-4658.2007.06042.x","article-title":"Pharmacologic chaperoning as a strategy to treat Gaucher disease","volume":"274","author":"Yu","year":"2007","journal-title":"FEBS J"},{"key":"2022011201141290100_stem1732-bib-0012","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"2022011201141290100_stem1732-bib-0013","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of \u03b2-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J"},{"key":"2022011201141290100_stem1732-bib-0014","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid \u03b2-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2011","journal-title":"J Biol Chem"},{"key":"2022011201141290100_stem1732-bib-0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"2022011201141290100_stem1732-bib-0016","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"2022011201141290100_stem1732-bib-0017","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","article-title":"Disease-specific induced pluripotent stem cells","volume":"134","author":"Park","year":"2008","journal-title":"Cell"},{"key":"2022011201141290100_stem1732-bib-0018","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"2022011201141290100_stem1732-bib-0019","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-med-050311-163324","article-title":"Reprogrammed cells for disease modeling and regenerative medicine","volume":"64","author":"Cherry","year":"2013","journal-title":"Annu Rev Med"},{"key":"2022011201141290100_stem1732-bib-0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nature10761","article-title":"The promise of induced pluripotent stem cells in research and therapy","volume":"481","author":"Robinton","year":"2012","journal-title":"Nature"},{"key":"2022011201141290100_stem1732-bib-0021","doi-asserted-by":"crossref","first-page":"18054","DOI":"10.1073\/pnas.1207889109","article-title":"Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease","volume":"109","author":"Panicker","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011201141290100_stem1732-bib-0022","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1093\/nar\/25.18.3745","article-title":"A transgenic mouse strain expressing four drug-selectable marker genes","volume":"25","author":"Tucker","year":"1997","journal-title":"Nucl Acids Res"},{"key":"2022011201141290100_stem1732-bib-0023","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/stemcells.2008-1075","article-title":"Induced pluripotent stem cell generation using a single lentiviral stem cell cassette","volume":"27","author":"Sommer","year":"2009","journal-title":"Stem Cells"},{"key":"2022011201141290100_stem1732-bib-0024","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/(SICI)1096-8628(19981204)80:4<343::AID-AJMG8>3.0.CO;2-W","article-title":"Mutation analysis of Gaucher disease patients from Argentina: High prevalence of the RecNciI mutation","volume":"80","author":"Cormand","year":"1998","journal-title":"Am J Med Genet"},{"key":"2022011201141290100_stem1732-bib-0025","doi-asserted-by":"crossref","first-page":"14234","DOI":"10.1073\/pnas.1103509108","article-title":"Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors","volume":"108","author":"Ban","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011201141290100_stem1732-bib-0026","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ymgme.2011.06.008","article-title":"Aggregation of-\u03b1-synuclein in brain samples from subjects with glucocerebrosidase mutations","volume":"104","author":"Choi","year":"2011","journal-title":"Mol Genet Metab"},{"key":"2022011201141290100_stem1732-bib-0027","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/intimm\/dxh328","article-title":"Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity","volume":"17","author":"Eijk","year":"2005","journal-title":"Int Immunol"},{"key":"2022011201141290100_stem1732-bib-0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.188.1.217","article-title":"Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I","volume":"188","author":"Sutterwala","year":"1998","journal-title":"J Exp Med"},{"key":"2022011201141290100_stem1732-bib-0029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","article-title":"Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease","volume":"23","author":"Hollak","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"2022011201141290100_stem1732-bib-0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0925-4439(96)00056-7","article-title":"Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease","volume":"1317","author":"Michelakakis","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"2022011201141290100_stem1732-bib-0031","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/8904_2012_184","article-title":"Biochemical and molecular chitotriosidase profiles in patients with Gaucher disease type 1 in Minas Gerais, Brazil: New mutation in CHIT1 gene","volume":"9","author":"Adelino","year":"2012","journal-title":"JIMD Rep"},{"key":"2022011201141290100_stem1732-bib-0032","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0074-7696(06)52001-7","article-title":"The biology of the Gaucher cell: The cradle of human chitinases","volume":"252","author":"Bussink","year":"2006","journal-title":"Int Rev Cytol"},{"key":"2022011201141290100_stem1732-bib-0033","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"2022011201141290100_stem1732-bib-0034","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/cbic.200800304","article-title":"Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on \u03b2-glucocerebrosidase by hydrogen\/deuterium exchange mass spectrometry","volume":"9","author":"Tropak","year":"2008","journal-title":"Chembiochem"},{"key":"2022011201141290100_stem1732-bib-0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bebdikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis."},{"key":"2022011201141290100_stem1732-bib-0036","first-page":"590","article-title":"An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells","volume":"58","author":"Naito","year":"1988","journal-title":"Lab Invest"},{"key":"2022011201141290100_stem1732-bib-0037","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5858\/2004-128-1191-EIGC","article-title":"Erythrophagocytosis in Gaucher cells","volume":"128","author":"Bitton","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"2022011201141290100_stem1732-bib-0038","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011201141290100_stem1732-bib-0039","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2164-12-20","article-title":"Global gene expression profile progression in Gaucher disease mouse models","volume":"12","author":"Xu","year":"2011","journal-title":"BMC Genomics"},{"key":"2022011201141290100_stem1732-bib-0040","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood.V93.5.1456","article-title":"Interleukin-10 inhibits expression of both interferon-\u03b1- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1","volume":"93","author":"Ito","year":"1999","journal-title":"Blood"},{"key":"2022011201141290100_stem1732-bib-0041","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/107999099313695","article-title":"The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes","volume":"19","author":"Donnelly","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"2022011201141290100_stem1732-bib-0042","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","article-title":"The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients","volume":"84","author":"Taddei","year":"2009","journal-title":"Am J Hematol"},{"key":"2022011201141290100_stem1732-bib-0043","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00277-008-0441-8","article-title":"Immunoglobulin and free light chain abnormalities in Gaucher disease type I: Data from an adult cohort of 63 patients and review of the literature","volume":"87","author":"Fost","year":"2008","journal-title":"Ann Hematol"},{"key":"2022011201141290100_stem1732-bib-0044","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1073\/pnas.1200941109","article-title":"Gaucher disease gene GBA functions in immune regulation","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011201141290100_stem1732-bib-0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/path.4227","article-title":"B cell lymphoma and myeloma in murine Gaucher\u2019s disease","volume":"231","author":"Pavlova","year":"2013","journal-title":"J Pathol."},{"key":"2022011201141290100_stem1732-bib-0046","first-page":"868","article-title":"Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors","volume":"24","author":"Torcia","year":"1996","journal-title":"Exp Hematol"},{"key":"2022011201141290100_stem1732-bib-0047","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(05)70115-5","article-title":"The role of interleukin-1 \u03b2 in the pathogenesis of multiple myeloma","volume":"13","author":"Lust","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022011201141290100_stem1732-bib-0048","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/eji.201141550","article-title":"A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation","volume":"41","author":"Dinarello","year":"2011","journal-title":"Eur J Immunol"},{"key":"2022011201141290100_stem1732-bib-0049","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2796.2010.02313.x","article-title":"Blocking interleukin-1\u03b2 in acute and chronic autoinflammatory diseases","volume":"269","author":"Dinarello","year":"2011","journal-title":"J Intern Med"},{"key":"2022011201141290100_stem1732-bib-0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","article-title":"Effect of enzyme replacement therapy on gammopathies in Gaucher disease","volume":"32","author":"Brautbar","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"2022011201141290100_stem1732-bib-0051","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bcmd.2009.04.002","article-title":"Gaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy","volume":"43","author":"Grosbois","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"2022011201141290100_stem1732-bib-0052","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10545-010-9241-0","article-title":"Gaucher disease with foamy transformed macrophages and erythrophagocytic activity","volume":"34","author":"Machaczka","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"2022011201141290100_stem1732-bib-0053","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0009-9120(98)00030-7","article-title":"Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT)","volume":"31","author":"Czartoryska","year":"1998","journal-title":"Clin Biochem"},{"key":"2022011201141290100_stem1732-bib-0054","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: A 2-center retrospective analysis","volume":"108","author":"Fost","year":"2006","journal-title":"Blood"},{"key":"2022011201141290100_stem1732-bib-0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrd708","article-title":"Targeting glycosylation as a therapeutic approach","volume":"1","author":"Dwek","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"2022011201141290100_stem1732-bib-0056","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1016\/S0021-9258(19)39223-3","article-title":"Analyses of catalytic activity and inhibitor binding of human acid \u03b2-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations","volume":"265","author":"Grace","year":"1990","journal-title":"J Biol Chem"},{"key":"2022011201141290100_stem1732-bib-0057","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant \u03b2-glucocerebrosidase in plant cells: Evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol Genet Metab"},{"key":"2022011201141290100_stem1732-bib-0058","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.ejhg.5200974","article-title":"Transient expression of wild-type and mutant glucocerebrosidases in hybrid vaccinia expression system","volume":"11","author":"Hodanova","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"2022011201141290100_stem1732-bib-0059","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cmdc.201000469","article-title":"Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease","volume":"6","author":"Oulaidi","year":"2011","journal-title":"Chem Med Chem"},{"key":"2022011201141290100_stem1732-bib-0060","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid \u03b2-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.1732","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/stem.1732","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/stem.1732","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/32\/9\/2338\/41984526\/stmcls_32_9_2338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/32\/9\/2338\/41984526\/stmcls_32_9_2338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T21:53:20Z","timestamp":1642542800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/32\/9\/2338-2349\/6422997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,18]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/stem.1732","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,1]]},"published":{"date-parts":[[2014,8,18]]}}}